SUGAZIDEM® – AV Injection

Description

Composition (Per Vial):

• Ceftazidime – 2000 mg

• Avibactam Sodium – Equivalent to 500 mg Avibactam
  Form: Powder for reconstitution
  Route of Administration: Intravenous infusion only
  Pack Size: Single-use vial with sterile diluent
  Category: Anti-MDR Antibiotic | β-lactam/β-lactamase inhibitor | ICU/critical care therapy

---

Product Description:

SUGAZIDEM® – AV combines Ceftazidime, a third-generation cephalosporin, with Avibactam, a novel non-β-lactam β-lactamase inhibitor. This cutting-edge combination provides extended-spectrum activity against serious multi-drug resistant Gram-negative bacteria, including Klebsiella pneumoniae carbapenemase (KPC) and OXA-48 producing Enterobacteriaceae.

Used in life-threatening infections where other antibiotics have failed, SUGAZIDEM® – AV is a frontline choice in hospital-acquired infections (HAIs), complicated UTIs, RTIs, and intra-abdominal infections.

---

Key Benefits:

• Active against carbapenem-resistant Enterobacteriaceae (CRE) and Pseudomonas aeruginosa

• Excellent option for ICU patients with limited treatment choices

• High penetration in lungs, urinary tract, and intra-abdominal tissues

• Preserves carbapenems as a last-resort option

---

How It Works:

• Ceftazidime inhibits bacterial cell wall synthesis, causing lysis.

• Avibactam protects ceftazidime from degradation by Class A, C, and some D β-lactamases (including KPC & OXA-48), restoring its antibacterial effect.

This synergistic mechanism overcomes key resistance mechanisms seen in ESBLs, AmpC, and carbapenemase-producing organisms.

---

How to Use:

• Reconstitute with the provided diluent and further dilute in 100ml NS

• Administer as IV infusion over 2 hours

• Recommended dose: 2.5g (Ceftazidime 2g + Avibactam 0.5g) every 8 hours

• Dose modification needed in renal impairment

• For hospital and ICU use only under specialist supervision

---

Safety Advice:

• Monitor renal function and adjust dose accordingly

• Watch for Clostridioides difficile-associated diarrhea during/after therapy

• Avoid in patients with severe hypersensitivity to β-lactams

• Not recommended in children <18 years unless prescribed by an infectious disease specialist

---

Precautions:

• Contraindicated in patients with:

  • Known β-lactam allergy

  • Severe renal dysfunction without dose adjustment

• Caution in:

  • Elderly, immunocompromised, or those with severe hepatic impairment

• Use only when sensitivity confirmed or highly suspected MDR infection

• Use within 12 hours of reconstitution if stored at 2–8°C

• Do not mix with other drugs or infuse concurrently in the same line